Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group

Trial Profile

Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Trabectedin (Primary)
  • Indications Meningioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Feb 2016 New source identified and integrated (United Kingdom Clinical Research Network; 20311)
    • 21 Sep 2015 According to EORTC and PharmaMar media release, company has enrolled first patient for this trial.
    • 16 Jul 2015 Planned primary completion date changed from 1 Mar 2017 to 1 Jul 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top